Matrix metalloprotease inhibitor

Details Matrix metalloprotease inhibitor Matrix metalloprotease inhibitor

2002-09-27

2009-11-17

Tate, Christopher R. (Department: 1655)

Drug, bio-affecting and body treating compositions

Extract or material containing or obtained from a...

Reexamination Certificate

active

07618638

ABSTRACT:
The object of the present invention is to provide a preventive and relieving medicine for activated matrix metalloproteinase-causing disorders and diseases, which contains a solvent extract ofGanodermamushroom.The preventive and relieving medicine for activated matrix metalloproteinase (MMP)-causing disorders and diseases according to the present invention contains the solvent extract ofGanodermamushroom. The solvent extract ofGanodermamushroom has MMP inhibiting behaviors and is effective for prevention, suppression, and symptomatic relief of various activated MMP-causing disorders and diseases, such as metastasis of cancers, ulceration, rheumatoid arthritis, osteoporosis, periodontitis, and aging of skin.

REFERENCES:
patent: 1157151 (1997-08-01), None
patent: 1291511 (2001-04-01), None
patent: 62-239953 (1987-10-01), None
patent: 6-345636 (1994-12-01), None
patent: 8-73369 (1996-03-01), None
patent: 9-40552 (1997-02-01), None
patent: 9-235293 (1997-09-01), None
patent: 11-139947 (1999-05-01), None
patent: 11-139947 (1999-07-01), None
patent: 11180889 (1999-07-01), None
Furusawa et al Phytotherapy Res, 1992, 6:300-304.
Yongfa et al., “The Preparation of a Solid Extract of Tai Mountain Ganoderma Lucidum,” Weifang Medical School Journal 2001 vol. 23 No. 1.
Zhang et al., The Formulation Design and Development Pathway of Dark Colored Foods, Chinese Food and Nutrition Mar. 1999.
Chinese Office Action dated Jul. 22, 2005 from corresponding Japanese Application (English Translation included).
Russian Office Action dated Mar. 18, 2005 from corresponding Russian Application (English Translation included).
Lovy et al., “Activity of Edible Mushrooms Against the Growth of Human T4Leukemic Cancer Cells, HeLa Cervical Cancer Cells, and Plasmodium falciparum”, 1999, Journal of Herbs, Spices & Medicinal Plants, vol. 6(4).
Yip et al., “Matrix metalloproteinase inhibitors: applications in oncology”, 1999, Investigational New Drugs.
Canadian Office Action dated Oct. 19, 2006, from corresponding Canadian Application No. 2,460,834.
Tanaka et al., “Effects of Magojakushi and Reishi on the production of collagen and glysosaminoglycans in cultured human dermal fibroblasts”, 1992, Journal of Medical and Pharmaceutical Society for Wakan-Yaku, vol. 9, No. 3, pp. 209-213.
Morigiwa et al., “Angiotensin Converting Enzyme-Inhibitory Triterpenes fromGanoderma lucidum”, 1986, Chem. Pharm. Bull., vol. 34, No. 7, pp. 3025-3028.
Choj et al., “Fibrinolytic and antithrombotic protease fromGanoderma lucidum”, 2000, Mycologia, vol. 92, No. 3, pp. 545-552.
Okamoto et al., Black Reishi (Ganoderma lucidum, Black), 1997, Food Reviews International, vol. 13, No. 3, pp. 370-373.
Schoenermark, et al., “Retinoid-Mediated Suppression of Tumor Invasion and Matrix Metalloproteinase Synthesis”, 2001, Annals New York Academy of Sciences, pp. 465-485.
“Brewing Society of Japan”, vol. 85, No. 6, pp. 385-392, issued in 1990 (partial translation).
“Anti-invasive activity of torilin, a sesquiterpene compound isolated fromTorilis japonica”, Kim MS, Baek JH, Park MT, Sohn TK, Kim SE, Lee JJ, Kim KW, Oncol Rep, Mar.-Apr. 2001; 8(2):359-64, Abstract.

Affiliated with

Also associated with

Rating

Matrix metalloprotease inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix metalloprotease inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloprotease inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4089336